Yoshito Komatsu
Hokkaido University
338 Papers
1.1K Citations
Yoshito Komatsu is an academic researcher from Hokkaido University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 278 publications.
Chat about Author
Papers
Study on the effect of a new anti-ulcer agent, ecabet sodium, on the dual therapy for eradication of Helicobacter pylori in randomized patients
Hidetoshi Kagaya,Mototsugu Kato,Tatsuya Kobayashi,Jun Ishizuka,K. Nishikawa,Yoshito Komatsu,M Sukegawa,Hiroshi Takeda,Toshihiro Sugiyama,Masahiro Asaka +9 more
5
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Yasuyuki Kawamoto,Yoshito Komatsu,Satoshi Yuki,Kentaro Sawada,Tetsuhito Muranaka,Kazuaki Harada,Hiroshi Nakatsumi,Hiraku Fukushima,Atsushi Ishiguro,Masayoshi Dazai,Kazuteru Hatanaka,Michio Nakamura,Ichiro Iwanaga,Minoru Uebayashi,Susumu Sogabe,Yoshimitsu Kobayashi,Takuto Miyagishima,Kota Ono,Naoya Sakamoto,Yuh Sakata +19 more
TL;DR: A combination of S-1, nab-paclitaxel and oxaliplatin (which the authors named ‘SNOW regimen’) can be a promising triplet therapy for advanced gastric cancer and it is aimed to investigate the recommended dose of this regimen in a phase I study and investigate its efficacy and toxicity in aphase II study.
A multicentre phase I/II study of TAS-102 with nintedanib in patients with metastatic colorectal cancer refractory to standard therapies (N-TASK FORCE: EPOC1410); Phase I results
Tomohiro Nishina,Yasutoshi Kuboki,Eiji Shinozaki,Shota Fukuoka,Takeshi Kajiwara,K. Shitara,Kensei Yamaguchi,Yoshito Komatsu,Satoshi Yuki,Kentaro Yamazaki,Hiroki Hara,N. Mochizuki,Miki Fukutani,H. Hasegawa,S. Matsuda,Masashi Wakabayashi,Shogo Nomura,A. Sato,A. Ohtsu,Takayuki Yoshino +19 more
5
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
Shunsuke Sakai,Masato Aoshima,Kentaro Sawada,Satoshi Horasawa,Ayumu Yoshikawa,Takao Fujisawa,Shigenori Kadowaki,Tadamichi Denda,Nobuhisa Matsuhashi,Hisateru Yasui,Masahiro Goto,Kentaro Yamazaki,Yoshito Komatsu,Ryota Nakanishi,M. Nakamura,Hideaki Bando,Yamato Hamaya,Shun-ichiro Kageyama,Takayuki Yoshino,Katsuya Tsuchihara,Riu Yamashita +20 more
TL;DR: It is shown that a stoma alters the taxonomic and functional profiles in feces and may be a confounding factor in fecal microbiota analysis, suggesting that the feces of patients with aStoma have a reduced abundance of favorable microbes for cancer immunotherapy.
Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).
Satoshi Yuki,Makio Gamoh,Tadamichi Denda,Atsuo Takashima,Shin Takahashi,Masato Nakamura,Hisatsugu Ohori,Tatsuro Yamaguchi,Yoshimitsu Kobayashi,Hideo Baba,Masanori Kotake,Kenji Amagai,Hitoshi Kondo,Ken Shimada,Atsushi Sato,Chikashi Ishioka,Keigo Komine,Kota Ouchi,Satoshi Morita,Yoshito Komatsu +19 more
TL;DR: The TRICOLORE trial previously demonstrated that S-1+IRI+Bmab (Arm B) was non-inferior to mFOLFOX6/CapeOX+B mab in terms of progression-free survival (PFS) as first-line treat...
5